Skip to content
OpenCapital
Get started

Danaher DHR Biotechnology — Operating Income (Loss)

Other segment segments

Diagnostics
$713M—
Life Sciences
$336M—

Similar metrics at other companies

JAN
JANBiotech — Operating Income
-$177K+67.2%
Alset Inc. logo
AEIBiohealth Business — Operating Income
-$97.62K+81.0%
CNT
CNTNClinical Stage Bio Technology — Operating Income
-$1.65M+35.3%
Denali Therapeutics Inc. logo
DNLITherapeutics Segment — Operating Income (Loss)
-$137.36M+5.6%
Ashland logo
ASHLife Sciences — Operating Income
$35M+25.0%
Duos Technologies Group, Inc. logo
DUOTTechnologies — Operating Income
-$2.31M-31.4%

Other financials

Income statement

See full
Revenue$6.3B+5.5%
Gross profit$3.6B+2.5%
Operating income$1.1B+48.3%
Net income$870.0M+56.8%
EPS (diluted)$1.23+59.7%

Balance sheet

See full
Cash & equivalents$4.3B+47.0%
Total debt$27.9B+50.1%
Total equity$52.6B+0.5%
Total assets$92.4B+13.2%

Cash flow

See full
Operating cash flow$1.5B+14.6%
CapEx$269.0M+8.5%
Free cash flow$1.3B+16.1%

Valuation

See full
Market cap$134.62B-7.4%
Enterprise value$158.13B-1.7%
P/E33.6×-9.0×
P/S5.4×-0.7×

Profitability

See full
Gross margin58.5%-1.1pp
Operating margin20.4%+2.0pp
Net margin15.9%+1.7pp
FCF margin21.8%+1.5pp

Returns & leverage

See full
Return on equity7.6%+1.0pp
Debt / equity0.5×+0.2×
Current ratio1.7×0.0×

Where this comes from

Reported directly by Danaher in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Danaher’s 10-Q, filed July 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Danaher's biotechnology — operating income (loss).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Danaher's biotechnology — operating income (loss)?
Danaher (DHR) reported biotechnology — operating income (loss) of $556M in Q2 2026.
How has Danaher's biotechnology — operating income (loss) changed year-over-year?
Danaher's biotechnology — operating income (loss) increased by 4.7% year-over-year, from $531M to $556M.
What is the long-term trend for Danaher's biotechnology — operating income (loss)?
Over 2 years (2023 to 2025), Danaher's biotechnology — operating income (loss) has grown at a -1.2% compound annual growth rate (CAGR), from $1.91B to $1.86B.
What does biotechnology — operating income (loss) mean?
The profit or loss generated by the biotechnology segment after deducting operating expenses from total revenue. This is the primary measure of the segment's core operational performance and profitability. It excludes interest, taxes, and corporate-level allocations to isolate the segment's efficiency.